[Metabolic syndrome and breast cancer risk in post-menopausal women].
Lipid metabolism disorders--breast cancer risk association in postmenopausal women was searched in many studies; the HDL-cholesterol value triggered most of controversies. Some authors plead for increased breast cancer risk in overweight/obese postmenopausal women if HDL is higher while others plead for higher risk if HDL is lower then in general population.


METHODS
We studied a 110 subjects female population aged between 41 and 69, and determined height, weight, body mass index (BMI), abdominal perimeter (AP), lipid parameters (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides). All women performed mammography and breast echography. Imagery divided the subjects in three groups: 30 breast cancer patients (first diagnosis)--group 1, 50 breast dysplasia women--group 2, and normal breast patients--group 3.


RESULTS
HDL-cholesterol proved significantly higher in group 2 compared to group 3 (control group), by the third and the fourth quartile; the same when it came to overweight/obese post-menopausal women. Nevertheless, more lipid disorders clustered in group 1 obese/overweight postmenopausal women.


CONCLUSIONS
High HDL in breast dysplasia women is reported in international studies too. High menopause prevalence in group 3, implying abdominal obesity and lipid disorders may explain the small difference between group 1 (breast cancer patients) and group 3 (control group). High clustering in group 1 pleads for increased breast cancer risk in metabolic syndrome postmenopausal women. Comparing HDL values and the clustering phenomenon in group 1 to the other two groups considered as a control population (as done in international published studies), we can conclude that low HDL--abdominal obesity association increases breast cancer risk after the menopausal age.
Petrovanu
Cynthia
C
Facultatea de Medicină, Disciplina Medicină de Familie, Universitatea de Medicină si Farmacie "Gr,T. Popa" Iaşi.
Coman
Adorata Elena
AE
Murariu
G C
GC
Petrovanu
Rodica
R
D000368:Aged; D015415:Biomarkers / Q000097:blood; D001827:Body Height; D015992:Body Mass Index; D001835:Body Weight; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008327:Mammography / Q000379:methods; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D008875:Middle Aged; D056128:Obesity, Abdominal / Q000097:blood / Q000150:complications; D017698:Postmenopause; D018570:Risk Assessment; D012383:Romania / Q000453:epidemiology; D014280:Triglycerides / Q000097:blood; D016217:Ultrasonography, Mammary / Q000379:methods; D055105:Waist Circumference
D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides